Literature DB >> 15618128

Proinflammatory cytokines and the hypermetabolism of children with sickle cell disease.

Jacqueline M Hibbert1, Lewis L Hsu, Sam J Bhathena, Ikovwa Irune, Bismark Sarfo, Melissa S Creary, Beatrice E Gee, Ali I Mohamed, Iris D Buchanan, Ahmad Al-Mahmoud, Jonathan K Stiles.   

Abstract

Sickle cell anemia (HbSS) includes chronic inflammation, but the origin is unclear. We hypothesized that in stable HbSS patients the inflammation was associated with hypermetabolism. We compared selected hypermetabolic and key immunomodulator indicators in HbSS versus control children and examined associations between measures of hypermetabolism and inflammation. Twelve fasting asymptomatic HbSS children 6-12 years and 9 controls matched for age, gender and fat mass (FM) were studied. Proportional reticulocyte count (retic%) and resting energy expenditure (REE) represented hypermetabolism, and C-reactive protein (CRP) indicated inflammation. Proinflammatory cytokines tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6), chemokine monocyte chemoattractant protein-1 (MCP-1), and energy balance cytokine leptin were measured. Methods were indirect calorimetry, enzyme-linked immunosorbent assay, and radioimmunoassay. Statistical analysis included simple correlation and regression analysis. REE (51 +/- 6 vs. 43 +/- 12 kcal/kg per fat-free mass (FFM), mean +/- SD), retic% (12 +/- 4 vs. 0.7 +/- 0.3%), CRP (5 +/- 3 vs. 0.3 +/- 0.4 mg/liter), and IL-6 (71 +/- 40 vs. 20 +/- 7 pg/ml) were significantly higher for HbSS than controls (P < 0.05). Conversely, leptin (0.1 +/- 0.1 vs. 2 +/- 1 microg/liter per kgFM) and MCP-1 (34 +/- 5 vs. 41 +/- 4 pg/ml) were significantly lower for the HbSS subjects (P < 0.01). TNF-alpha was not significantly different. There were no significant associations between REE or retic% and any cytokine measured. However, CRP was significantly associated with REE in HbSS (r = 0.8, P = 0.003) and an important predictor of REE/FFM. We provide new evidence for low circulating levels of inflammatory chemokine MCP-1 in stable HbSS children, confirm mostly low cytokine levels, inflammation, and hypermetabolism and demonstrate association of hypermetabolism with inflammation via CRP but not via cytokines.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15618128      PMCID: PMC4033607          DOI: 10.1177/153537020523000109

Source DB:  PubMed          Journal:  Exp Biol Med (Maywood)        ISSN: 1535-3699


  40 in total

1.  Alpha-2-macroglobulin and interleukin-6 levels in steady-state sickle cell disease patients.

Authors:  A C Makis; E C Hatzimichael; A Mavridis; K L Bourantas
Journal:  Acta Haematol       Date:  2000       Impact factor: 2.195

2.  Activated monocytes and platelet-monocyte aggregates in patients with sickle cell disease.

Authors:  Ted Wun; Miguel Cordoba; Arun Rangaswami; Anthony W Cheung; Teresa Paglieroni
Journal:  Clin Lab Haematol       Date:  2002-04

3.  Lysine turnover in man measured by intravenous infusion of L-[U-14C]lysine.

Authors:  J C Waterlow
Journal:  Clin Sci       Date:  1967-12       Impact factor: 6.124

4.  Energy intake and resting metabolic rate in preschool Jamaican children with homozygous sickle cell disease.

Authors:  Atul Singhal; Stephany Parker; Louise Linsell; Graham Serjeant
Journal:  Am J Clin Nutr       Date:  2002-06       Impact factor: 7.045

5.  Cytokine-driven inflammatory response is associated with the hypermetabolism of AIDS patients with opportunistic infections.

Authors:  P García-Lorda; P Serrano; M J Jiménez-Expósito; J Fraile; M Bulló; C Alonso; A Bonada; P Viciana; P P Luna; J Salas-Salvadó
Journal:  JPEN J Parenter Enteral Nutr       Date:  2000 Nov-Dec       Impact factor: 4.016

6.  Placenta growth factor activates monocytes and correlates with sickle cell disease severity.

Authors:  Natalya Perelman; Suresh K Selvaraj; Sandeep Batra; Lori R Luck; Anat Erdreich-Epstein; Thomas D Coates; Vijay K Kalra; Punam Malik
Journal:  Blood       Date:  2003-04-24       Impact factor: 22.113

7.  Plasma leptin association with body composition and energy expenditure in sickle cell disease.

Authors:  M S Buchowski; L A Simmons; K Y Chen; P J Flakoll; B G Mellen; E A Turner
Journal:  J Am Coll Nutr       Date:  2000-04       Impact factor: 3.169

8.  Transgenic sickle mice have vascular inflammation.

Authors:  John D Belcher; Christopher J Bryant; Julia Nguyen; Paul R Bowlin; Miroslaw C Kielbik; John C Bischof; Robert P Hebbel; Gregory M Vercellotti
Journal:  Blood       Date:  2003-01-23       Impact factor: 22.113

9.  Early nutrition and leptin concentrations in later life.

Authors:  Atul Singhal; I Sadaf Farooqi; Stephen O'Rahilly; Tim J Cole; Mary Fewtrell; Alan Lucas
Journal:  Am J Clin Nutr       Date:  2002-06       Impact factor: 7.045

10.  Leptin indirectly activates human neutrophils via induction of TNF-alpha.

Authors:  Hamid Zarkesh-Esfahani; Alan G Pockley; Zida Wu; Paul G Hellewell; Anthony P Weetman; Richard J M Ross
Journal:  J Immunol       Date:  2004-02-01       Impact factor: 5.422

View more
  42 in total

1.  Variable dietary management of methylmalonic acidemia: metabolic and energetic correlations.

Authors:  Natalie S Hauser; Irini Manoli; Jennifer C Graf; Jennifer Sloan; Charles P Venditti
Journal:  Am J Clin Nutr       Date:  2010-11-03       Impact factor: 7.045

2.  Frequent red cell transfusions reduced vascular endothelial activation and thrombogenicity in children with sickle cell anemia and high stroke risk.

Authors:  Hyacinth I Hyacinth; Robert J Adams; Jenifer H Voeks; Jacqueline M Hibbert; Beatrice E Gee
Journal:  Am J Hematol       Date:  2013-11-28       Impact factor: 10.047

3.  Impact of Bariatric Surgery on Outcomes of Patients with Sickle Cell Disease: a Nationwide Inpatient Sample Analysis, 2004-2014.

Authors:  Prabin Sharma; Thomas R McCarty; Siddhartha Yadav; Julius N Ngu; Basile Njei
Journal:  Obes Surg       Date:  2019-06       Impact factor: 4.129

4.  High protein diet attenuates histopathologic organ damage and vascular leakage in transgenic murine model of sickle cell anemia.

Authors:  Elizabeth Ann Manci; Hyacinth I Hyacinth; Patrice L Capers; David R Archer; Sydney Pitts; Samit Ghosh; John Patrickson; Michael E Titford; Solomon F Ofori-Acquah; Jacqueline M Hibbert
Journal:  Exp Biol Med (Maywood)       Date:  2014-05-19

5.  Developing new pharmacotherapeutic approaches to treating sickle-cell disease.

Authors:  Marilyn J Telen
Journal:  ISBT Sci Ser       Date:  2016-11-15

6.  TNF-α, IFN-γ, IL-10, and IL-4 levels were elevated in a murine model of human sickle cell anemia maintained on a high protein/calorie diet.

Authors:  Hyacinth I Hyacinth; Patrice L Capers; David R Archer; Jacqueline M Hibbert
Journal:  Exp Biol Med (Maywood)       Date:  2013-11-26

7.  Plasma interleukin-1beta concentration is associated with stroke in sickle cell disease.

Authors:  Kwaku Asare; Beatrice E Gee; Jonathan K Stiles; Nana O Wilson; Adel Driss; Alexander Quarshie; Robert J Adams; Abdullah Kutlar; Jacqueline M Hibbert
Journal:  Cytokine       Date:  2009-11-08       Impact factor: 3.861

8.  Skeletal muscle growth in young rats is inhibited by chronic exposure to IL-6 but preserved by concurrent voluntary endurance exercise.

Authors:  P W Bodell; E Kodesh; F Haddad; F P Zaldivar; D M Cooper; G R Adams
Journal:  J Appl Physiol (1985)       Date:  2008-12-04

9.  Increased levels of the inflammatory biomarker C-reactive protein at baseline are associated with childhood sickle cell vasocclusive crises.

Authors:  Suba Krishnan; Yamaja Setty; Suhita G Betal; Vaidyula Vijender; Koneti Rao; Carlton Dampier; Marie Stuart
Journal:  Br J Haematol       Date:  2009-12-08       Impact factor: 6.998

10.  Angiogenic and inflammatory markers of cardiopulmonary changes in children and adolescents with sickle cell disease.

Authors:  Xiaomei Niu; Mehdi Nouraie; Andrew Campbell; Sohail Rana; Caterina P Minniti; Craig Sable; Deepika Darbari; Niti Dham; N Scott Reading; Josef T Prchal; Gregory J Kato; Mark T Gladwin; Oswaldo L Castro; Victor R Gordeuk
Journal:  PLoS One       Date:  2009-11-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.